Task D25 EVALUATION OF ORTHOPOX VACCINATION IN AN AEROSOL MONKEYPOX MODEL

任务 D25 在气溶胶猴痘模型中评估正痘疫苗接种

• 批准号: 8160531
• 负责人: JANET HOLMBERG
• 金额: $ 104.91万
• 依托单位: LOVELACE BIOMEDICAL & ENVIRONMENTAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-27 至 2012-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8160531
• 关键词: Aerosols; Animal Model; Animals; Antimicrobial susceptibility; Bacteria; Categories; Clinical; Contracts; Development; Disease; Evaluation; In Vitro; Licensure; Modeling; Monkeypox; Orthopoxvirus; Standardization; Testing; Therapeutic; Vaccination; Vaccines; antimicrobial; biodefense; efficacy testing; nonhuman primate; pathogen; therapeutic vaccine; vaccine development

The In Vitro and Animal Models for Emerging Diseases and Biodefense contract provides antimicrobial activity testing capabilities for Category A-C bacteria. Compounds demonstrating antimicrobial activity will receive further antimicrobial susceptibility testing against clinical panels of emerging and Category A-C bacterial pathogens. This contract provides the development and standardization of small animal and non-human primate models, and may include efficacy testing of vaccines and/or therapeutics, including GLP studies to support product licensure. Vaccines and therapeutics which are efficacious in small animals may be further tested in non-human primate models.

新兴疾病和生物防御合同的体外和动物模型提供了A-C类细菌的抗菌活性测试能力。证明抗菌活性的化合物将接受针对新出现的和A-C类细菌病原体的临床组的进一步抗菌药物敏感性测试。该合同提供了小动物和非人灵长类动物模型的开发和标准化，可能包括疫苗和/或治疗剂的有效性测试，包括GLP研究以支持产品许可。在小动物中有效的疫苗和治疗剂可以在非人灵长类动物模型中进一步测试。